David Kirske - 30 Jun 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
30 Jun 2022
Net transactions value
-$94,426
Form type
4
Filing time
20 Sep 2022, 16:59:57 UTC
Previous filing
17 Jun 2022
Next filing
03 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Award $20,141 +9,516 +129% $2.12 16,913 30 Jun 2022 Direct F1
transaction CTIC common stock Options Exercise $21,438 +22,592 +134% $0.9489 39,505 16 Sep 2022 Direct
transaction CTIC common stock Sale $136,004 -22,592 -57% $6.02 16,913 16 Sep 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -22,592 -4.6% $0.000000 467,408 16 Sep 2022 Common Stock 22,592 $0.9489 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F2 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F3 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.